Successful Dartmouth TB Vaccine Moves Forward After Phase 2 Trial

Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine from a three-year trial in Tanzania were announced by investigators at Dartmouth’s Geisel School of Medicine and published in the journal Vaccine.
Source: News at Dartmouth Medical School - Category: Hospital Management Authors: Tags: News Press Release Research Tanzania tubercolosis Source Type: news

Related Links:

More effective tuberculosis vaccines are needed to help reach World Health Organization tuberculosis elimination goals. Insufficient evidence exists on the potential impact of future tuberculosis vaccines with varying characteristics and in different epidemiological settings. To inform vaccine development decision making, we modeled the impact of hypothetical tuberculosis vaccines in three high-burden countries. We calibrated Mycobacterium tuberculosis (M.tb) transmission models to age-stratified demographic and epidemiological data from China, South Africa, and India. We varied vaccine efficacy to prevent infection or dis...
Source: Science Translational Medicine - Category: Biomedical Science Authors: Tags: Research Articles Source Type: research
Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine from a three-year trial in Tanzania were announced by investigators at Dartmouth’s Geisel School of Medicine and published in the journal Vaccine.
Source: News at Dartmouth Medical School - Category: Hospital Management Authors: Tags: News Press Release Research Tanzania tubercolosis Source Type: news
(The Geisel School of Medicine at Dartmouth) Results from the Phase 2 trial of the DAR-901 tuberculosis (TB) vaccine were announced today by investigators at Dartmouth's Geisel School of Medicine and published in the journal Vaccine. The three-year trial was conducted among 650 adolescents in Tanzania, a nation with high rates of TB infection, and showed that the vaccine was safe and induced immune responses against the disease.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
Mycobacterium bovis could infect patients with immunodeficiency or immunosuppressive conditions via Bacillus Calmette-Gu érin (BCG) vaccination. Tuberculosis-related hemophagocytic syndrome (HPS) is reported, but ...
Source: BMC Infectious Diseases - Category: Infectious Diseases Authors: Tags: Case report Source Type: research
Condition:   Tuberculosis Interventions:   Biological: BCG vaccine 1(0.025mg/0.1ml/person);   Biological: BCG vaccine 2 (0.05mg/0.1ml/person);   Biological: BCG vaccine 3(0.075mg/0.1ml/person);   Biological: BCG vaccine 4 (0.075mg/0.1ml/person);   Biological: Placebo of BCG vaccine (0.1ml/person) Sponsor:   Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Mycobacterium tuberculosis (Mtb) infection is one of the leading causes of death worldwide. The Modified Vaccinia Ankara (MVA) vaccine vector expressing the mycobacterial antigen 85A (MVA85A) was demonstrated to be safe, although it did not improve BCG efficacy, denoting the need to search for improved tuberculosis vaccines. In this work, we investigated the effect of IL-12 DNA -as an adjuvant- on an Ag85A DNA prime/MVA85A boost vaccination regimen. We evaluated the immune response profile elicited in mice and the protection conferred against intratracheal Mtb H37Rv challenge. We observed that the immunization scheme inclu...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Bacillus Calmette-Guérin (BCG) vaccination induces variable protection against pulmonary tuberculosis (TB), and a more effective TB vaccine is needed. The potential for BCG to provide protection against heterologous infections, by induction of innate immune memory, is increasingly recognized. These nonspecific responses may substantially benefit public health, but are also variable. In this issue of the JCI, Koeken and de Bree et al. report that BCG reduces circulating inflammatory markers in males but not in females, while de Bree and Mouritis et al. describe how diurnal rhythms affect the degree of BCG-induced inn...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
CONCLUSIONS BCG vaccination in the morning induces stronger trained immunity and adaptive responses compared with evening vaccination. Future studies should take vaccine administration time into account when studying specific and nonspecific effects of vaccines; early morning should be the preferred moment of BCG administration.FUNDING The Netherlands Organization for Scientific Research, the European Research Council, and the Danish National Research Foundation.
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
More News: Hospital Management | Tanzania Health | Tuberculosis | Tuberculosis (BCG) Vaccine | Vaccines